Please login to the form below

Not currently logged in
Email:
Password:

Daklinza

This page shows the latest Daklinza news and features for those working in and with pharma, biotech and healthcare.

NICE backs three hepatitis C meds, turns down Duchenne drug

NICE backs three hepatitis C meds, turns down Duchenne drug

NICE issued positive final draft guidance for Gilead's Harvoni (sofosbuvir/ledipasvir), BMS' Daklinza (daclatasvir) and AbbVie's Viekirax (ombitasvir/paritaprevir/ritonavir), with or without Exviera (dasabuvir), making the new drugs ... Some patients

Latest news

More from news
Approximately 6 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics